Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies
文献类型：期刊论文
| 作者 | Liang, Xuewu1,4; Zang, Jie1; Li, Xiaoyang3; Tang, Shuai4; Huang, Min4 ; Geng, Meiyu4; Chou, C. James3; Li, Chunpu4; Cao, Yichun2; Xu, Wenfang1
|
| 刊名 | JOURNAL OF MEDICINAL CHEMISTRY
 |
| 出版日期 | 2019-04-25 |
| 卷号 | 62期号:8页码:3898-3923 |
| ISSN号 | 0022-2623 |
| DOI | 10.1021/acs.jmedchem.8b01597 |
| 通讯作者 | Liu, Hong(hliu@mail.shcnc.ac.cn) ; Zhang, Yingjie(zhangyingjie@sdu.edu.cn) |
| 英文摘要 | Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors. Here, a novel series of pyrimidin-2-amino-pyrazol hydroxamate derivatives as JAK and HDAC dual inhibitors was designed, synthesized, and evaluated, among which 8m possessed potent and balanced activities against both JAK2 and HDAC6 with half-maximal inhibitory concentration at the nanomolar level. 8m exhibited improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several hematological cell lines. Remarkably, 8m exhibited more potent antiproliferation effect than the combination of SAHA and ruxolitinib in HEL cells bearing JAK2(V617F) mutation. Pharmacokinetic studies in mice showed that 8m possessed good bioavailability after intraperitoneal administration. Finally, 8m showed antitumor efficacy with no significant toxicity in a HEL xenograft model. Collectively, the results confirm the therapeutic potential of JAK and HDAC dual inhibitors in hematological malignancies and provide valuable leads for further structural optimization and antitumor mechanism study. |
| WOS关键词 | POLYCYTHEMIA-VERA ; MUTATION ; ACTIVATION ; GROWTH ; POLYPHARMACOLOGY ; MYELOFIBROSIS ; MECHANISMS ; CHALLENGES ; RESISTANCE ; DESIGN |
| 资助项目 | National High-Tech R&D Program of China (863 Program)[2014AA020523] ; Natural Science Foundation of Shandong Province[ZR2018QH007] ; Major Project of Science and Technology of Shandong Province[2017CXGC1401] ; Young Scholars Program of Shandong University (YSPSDU)[2016WLJH33] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000466053900007 |
| 出版者 | AMER CHEMICAL SOC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/289905]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Liu, Hong; Zhang, Yingjie |
| 作者单位 | 1.Shandong Univ, Sch Pharm, Dept Med Chem, Jinan 250012, Shandong, Peoples R China 2.Fudan Univ, Sch Pharm, 826 Zhanghen Rd, Shanghai 201203, Peoples R China 3.Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Coll Pharm, Charleston, SC 29425 USA 4.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Liang, Xuewu,Zang, Jie,Li, Xiaoyang,et al. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies[J]. JOURNAL OF MEDICINAL CHEMISTRY,2019,62(8):3898-3923. |
| APA | Liang, Xuewu.,Zang, Jie.,Li, Xiaoyang.,Tang, Shuai.,Huang, Min.,...&Zhang, Yingjie.(2019).Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.JOURNAL OF MEDICINAL CHEMISTRY,62(8),3898-3923. |
| MLA | Liang, Xuewu,et al."Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies".JOURNAL OF MEDICINAL CHEMISTRY 62.8(2019):3898-3923. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。